Dyadic International, Inc.
Dyadic International, Inc.
Your view on DYAI
Overview
What the company does, where it operates, and who runs it.
About Dyadic International, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Emalfarb
- Headquarters
- 140 Intracoastal Pointe Drive, Jupiter, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Emalfarb
- Headquarters
- 140 Intracoastal Pointe Drive, Jupiter, FL, US
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.
The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.
The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited.
Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Dyadic International, Inc., and the rating behind it. DYAI last traded at $0.48; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Dyadic International, Inc.. Starting points for Dyadic International, Inc.: EPS -$0.21, beta 1.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Dyadic International, Inc.. Dyadic International, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Dyadic International, Inc.. Trailing twelve-month EPS for Dyadic International, Inc. stands at -$0.21. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Dyadic International, Inc.. Dyadic International, Inc. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Dyadic International, Inc. valued side by side against its closest peers. Dyadic International, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Dyadic International, Inc., and how their positions are changing. At a $17.6M market value, institutional positions materially move Dyadic International, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Dyadic International, Inc. executives and directors. Shares of Dyadic International, Inc. have traded between $0.71 and $2.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Dyadic International, Inc.. Dyadic International, Inc. is a $17.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Dyadic International, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Dyadic International, Inc.. Coverage tracks Dyadic International, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.